ADCT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors...

Stats
Šios dienos apimtis	321 167
Vidutinė apimtis	707 477
Rinkos kapitalizacija	359.41M
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-0.560 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.00900 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Redmile Group, Llc	Sell	59 986	Cash-settled Swaps
2024-02-01	Redmile Group, Llc	Sell	19 700	Cash-settled Swaps
2024-02-01	Redmile Group, Llc	Buy	205 483	Cash-settled Swaps
2024-01-31	Redmile Group, Llc	Buy	150 000	Cash-settled Swaps
2024-01-29	Redmile Group, Llc	Buy	150 000	Cash-settled Swaps

INSIDER POWER
-45.66
Last 79 transactions
Buy: 1 817 492 \| Sell: 5 217 316

Tūris Koreliacija

Ilgas: -0.02 (neutral)

Trumpas: 0.62 (weak)

Signal:(47.638) Neutral

ADC Therapeutics SA Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
K	0.945
NKX	0.942
OGN	0.941
JWN	0.941
SPCE	0.937
ZME	0.936
BIG	0.933
BBWI	0.933
GSL	0.933
USPH	0.931

10 Labiausiai neigiamai susiję koreliacijos
FLRT	-0.949
SLB	-0.944
CANE	-0.944
OII	-0.943
IEZ	-0.94
OIH	-0.937
WHD	-0.937
HAL	-0.935
AFT	-0.934
BKR	-0.933

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ADC Therapeutics SA Koreliacija - Valiuta/Žaliavos

0.63
( weak )

0.46
( neutral )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

-0.40
( neutral )

ADC Therapeutics SA Finansinės ataskaitos

Annual	2023
Pajamos:	$69.56M
Bruto pelnas:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2023
Pajamos:	$69.56M
Bruto pelnas:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2022
Pajamos:	$209.91M
Bruto pelnas:	$205.33M (97.82 %)
EPS:	$-1.990

FY	2021
Pajamos:	$33.92M
Bruto pelnas:	$32.52M (95.89 %)
EPS:	$-3.52

Financial Reports:

No articles found.

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.